Tuberculosis Treatment Market:By Class of Drugs (First Line Drugs, Second Line Drugs), By TB (TB, Multi Drug Resistance TB), by route of administration (Oral, Parental), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

   

Tuberculosis Treatment Market size was valued at USD 1.7 billion in 2021 and is expected to grow at a CAGR of 6.1% during 2022 to 2028. Tuberculosis is the infectious disease usually caused by the bacteria Mycobacterium tuberculosis. TB usually affects lungs and transmits to the direct contact with the sputum of the infected person. Global Tuberculosis Treatment Market is projected to grow at significant rates owing to increase in prevalence of the immunosuppressant diseases such as HIV around the globe. HIV infected patients are very susceptible to be infected by TB. According to UNAIDS statistics, about 36.7 million people were living with the HIV in 2016. Companies operating in the global market focusing on new product developments and launches to maximize their share in the market. Furthermore, collaborations and acquisitions are also key strategies adopted by the companies to strengthen their position in the global market. For instance, in August 2017, Johnson & Johnson Servieces Inc. has entered into the partnership with Institute of Microbial Technology to accelerate the discovery of novel treatments for tuberculosis. The rising number of medicine recalls is a key stumbling block to the market's expansion. Manufacturers of tuberculosis drugs face obstacles such as an increase in product recalls due to packaging or manufacturing defects. In India, for example, Sandoz recalled a batch of tuberculosis (TB) medications due to improper packaging. Furthermore, the Philippines Food and Medicine Administration recalled Novartis' drug Onecure in 2016 due to an insufficient amount of rifampicin in the drug. Another element limiting the market's growth is the high cost of medications. Second-line therapy medications are more expensive than first-line treatment drugs, and they have more side effects and high levels of toxicity. Although advanced technologies and the development of novel therapies are expected to reduce the time it takes to treat tuberculosis, most cases can take up to 6 months to treat with currently available drugs. Despite existing medicines and ongoing TB treatment drug advances, there is a constant need to increase patients' access to appropriate TB medicines, particularly in the areas of MDR TB and paediatric TB.